{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:25:53Z","timestamp":1792657553927,"version":"4.5.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T00:00:00Z","timestamp":1376956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:sec><jats:title>Aim(s)<\/jats:title><jats:p>This study assessed the effect of differences in renal function on the pharmacokinetics and pharmacodynamics of dapagliflozin, a renal sodium glucose co\u2010transporter\u20102<jats:styled-content style=\"fixed-case\">(SGLT2)<\/jats:styled-content>inhibitor for the treatment of type 2 diabetes mellitus (<jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single 50\u2009mg dose of dapagliflozin was used to assess pharmacokinetics and pharmacodynamics in five groups: healthy non\u2010diabetic subjects; patients with<jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>and normal kidney function and patients with<jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>and mild, moderate or severe renal impairment based on estimated creatinine clearance. Subsequently, 20\u2009mg once daily multiple doses of dapagliflozin were evaluated in the patients with<jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>. Formation rates of dapagliflozin 3\u2010<jats:italic>O<\/jats:italic>\u2010glucuronide (<jats:styled-content style=\"fixed-case\">D3OG<\/jats:styled-content>), an inactive metabolite, were evaluated using human isolated kidney and liver microsomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Plasma concentrations of dapagliflozin and<jats:styled-content style=\"fixed-case\">D3OG<\/jats:styled-content>were incrementally increased with declining kidney function. Steady\u2010state<jats:styled-content style=\"fixed-case\"><jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub><\/jats:styled-content>for dapagliflozin were 4%, 6% and 9% higher and for<jats:styled-content style=\"fixed-case\">D3OG<\/jats:styled-content>were 20%, 37% and 52% higher in patients with mild, moderate and severe renal impairment, respectively, compared with normal function.<jats:styled-content style=\"fixed-case\">AUC(0,\u03c4)<\/jats:styled-content>was likewise higher.<jats:styled-content style=\"fixed-case\">D3OG<\/jats:styled-content>formation in kidney microsomes was three\u2010fold higher than in liver microsomes and 109\u2010fold higher than in intestine microsomes. Compared with patients with normal renal function, pharmacodynamic effects were attenuated with renal impairment. Steady\u2010state renal glucose clearance was reduced by 42%, 83% and 84% in patients with mild, moderate or severe renal impairment, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results indicate that both kidney and liver significantly contribute to dapagliflozin metabolism, resulting in higher systemic exposure with declining kidney function. Dapagliflozin pharmacodynamics in diabetic subjects with moderate to severe renal impairment are consistent with the observation of reduced efficacy in this patient population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12056","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T20:39:30Z","timestamp":1354653570000},"page":"432-444","source":"Crossref","is-referenced-by-count":101,"title":["The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus"],"prefix":"10.1111","volume":"76","author":[{"given":"Sreeneeranj","family":"Kasichayanula","sequence":"first","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Co Princeton NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoni","family":"Liu","sequence":"additional","affiliation":[{"name":"Global Biometric Sciences Bristol\u2010Myers Squibb Co Princeton NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Pe Benito","sequence":"additional","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Co Princeton NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization Bristol\u2010Myers Squibb Co Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Co Princeton NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank P.","family":"LaCreta","sequence":"additional","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Co Princeton NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Griffith","family":"Humphreys","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization Bristol\u2010Myers Squibb Co Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Boulton","sequence":"additional","affiliation":[{"name":"Discovery Medicine and Clinical Pharmacology Bristol\u2010Myers Squibb Co Princeton NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,20]]},"reference":[{"issue":"1","key":"e_1_2_9_2_1","first-page":"S94","article-title":"Diabetic nephropathy","volume":"26","author":"Molitch ME","year":"2003","journal-title":"Diabetes Care"},{"key":"e_1_2_9_3_1","first-page":"43","article-title":"Type II diabetes: a treatment approach for the older patient","volume":"51","author":"Miller M","year":"1996","journal-title":"Geriatrics"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.87"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116972"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000092790.89332.D2"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01746.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.14.6.782"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3427"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm701272q"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1472"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0612"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02911.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.251"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029165"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.011"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365519009091579"},{"key":"e_1_2_9_23_1","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research (CDER).Guidance for industry: pharmacokinetics in patients with impaired renal function \u2013 study design data analysis and impact on dosing and labeling.1998. US FDA Web site. Available athttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072127.pdf(last accessed 24 October 2011)."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra054415"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.250"},{"issue":"1","key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.2337\/diacare.25.2007.S85","article-title":"Diabetic nephropathy (position statement)","volume":"25","author":"American Diabetes Association","year":"2002","journal-title":"Diabetes Care"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e3283136732"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0678-8"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac201704a"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.21.357"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0031-6997(24)01351-6","article-title":"Renal drug metabolism","volume":"50","author":"Lohr JW","year":"1998","journal-title":"Pharmacol Rev"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1088\/0143-0815\/10\/3\/001"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.12.019"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602530903208579"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12056","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:28:16Z","timestamp":1745393296000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,20]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/bcp.12056"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12056","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,20]]}}}